bioMerieux (FR:BIM) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
bioMerieux, a leader in in vitro diagnostics, reported a robust first-half of 2024 with a 9.9% organic sales growth to €1,902 million, and a significant 33% increase in net income compared to the previous year. The company’s strategic GO•28 plan and recent FDA approvals have propelled the growth, leading bioMerieux to raise its full-year guidance for both sales and CEBIT. The positive financial performance was partly offset by a negative currency impact.
For further insights into FR:BIM stock, check out TipRanks’ Stock Analysis page.
